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Vascular diseases of the cerebral circulation represent a com-
plex and diverse spectrum of pathology. Within the cere-
brovascular field, there have been numerous recent advances
in patient diagnosis, evaluation, imaging analysis, medical
therapies, microsurgical treatments, and minimally inva-
sive therapeutic modalities. These improvements have been
driven by research developments from in vitro, in vivo,
translational, and clinical studies. We review and add to the
primary literature concerning this special issue.
Stroke is a major cause of morbidity and mortality.
Although intravenous tissue plasminogen activator has been
a validated medical therapy in patients with acute ischemic
stroke, there are many patients who fail to meet the defined
time window for treatment. Neuroprotective agents for acute
stroke could provide a major therapeutic advantage for many
patients. In this issue, H.-K. Liew et al. demonstrate that
“Granulocyte-Colony Stimulating Factor Increases Cerebral
Blood Flow via a NO Surge Mediated by Akt/eNOS Pathway
to Reduce Ischemic Injury.” Further studies are indicated
to better define potential alternative medical therapies in
acute ischemic stroke patients. Although earlier randomized
clinical trials (RCTs) challenged the use of endovascular
therapy in acute cerebrovascular occlusion [1–3], refine-
ments in patient selection and three recent RCTs have vali-
dated the benefit of endovascular mechanical thrombectomy,
preferably with retrievable stents (i.e., stentrievers), in
patients with large vessel occlusion [4, 5]. Limitations of prior
RCTs of endovascular stroke intervention included the use
of earlier generation thrombectomy devices. In this issue,
O. Ozdemir et al. provide us with “Predictors of a Good
Outcome after Endovascular Stroke Treatment with Stent
Retrievers”.
Long-term follow-up in the International Study of Un-
ruptured Intracranial Aneurysms (ISUIA) [6] and the Inter-
national Subarachnoid Hemorrhage Aneurysm Trial (ISAT)
has validated both microsurgical clipping and endovascu-
lar coiling in the treatment of ruptured and unruptured
aneurysms [7]. As these outcomes are based on patients
who were primarily treated during the 1990s, they may
be based on antiquated means of patient evaluation and
treatment. Recently, there have been many advances in
medical therapies, imaging, microsurgical treatment, and
endovascular therapies for cerebral aneurysms [8]. In the
current issue, N. Ajiboye et al. provide us with an update on
“Unruptured Cerebral Aneurysms: Evaluation and Manage-
ment.” Cerebral vasospasm continues to be a leading cause of
morbidity andmortality following aneurysm rupture. Recent
RCTs have not provided us with further therapeutic strategies
[9]. Perhaps refinements in patient evaluation and selection
will improve patient outcomes. S. H. Sheen et al. provide
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a protocol on “Intravenous Flat-Detector Computed Tomog-
raphy Angiography for Symptomatic Cerebral Vasospasm
following Aneurysmal Subarachnoid Hemorrhage.” These
new imaging modalities may yield a less invasive means for
the evaluation and treatment of patients with aneurysmal
subarachnoid hemorrhage.
Recent RCTs and prospective cohort studies have chal-
lenged current management strategies for unruptured cere-
bral arteriovenousmalformations (AVMs), but these analyses
have not been without limitations [10, 11]. When indicated,
current AVM interventions include microsurgery, radio-
surgery, and embolization. These therapeutic options are
also often used individually or as part of a multimodality
approach. In this issue N. Ajiboye et al. provide us with
an update through “Cerebral Arteriovenous Malformations:
Evaluation and Management.” Additionally, S. Peschillo
et al. provide us with a review on treatment options in
“Brain AVMs: An Endovascular, Surgical, and Radiosurgical
Update.”
Neurovascular diseases are a heterogeneous group of dis-
orders that are often associated with poor clinical outcomes.
S. Tabuchi provides us with a review on “Auditory Dysfunc-
tion in Patients with Cerebrovascular Disease” and A. Y. Lu
et al. provide us with an assessment of “Hemifacial Spasm
and Neurovascular Compression.” Although the majority
of neurovascular diseases are primarily arterial pathologies,
cerebral venous diseasesmay also incur significantmorbidity.
To round out this issue, we provide an update and review
of “Endovascular Treatment of Venous Sinus Stenosis in
Idiopathic IntracranialHypertension: Complications,Neuro-
logicalOutcomes, andRadiographic Results.” Although cere-
brospinal fluid diversion has been a mainstay of treatment
in patients with idiopathic intracranial hypertension (IIH)
refractory to medical therapy, recent advances in endovascu-
lar therapies have provided an effective alternative treatment
option. Specifically, venous sinus stenting has been shown to
provide durable neurological improvement in IIH patients
with venous sinus stenosis and a significant physiologic
pressure gradient. Further studies regarding associated com-
plications, neurological outcomes, and radiographic results
are necessary.
Improvements in clinical evaluation, imaging, and treat-
ment will lead to better outcomes in patients with neurovas-
cular disease. Although there continue to be many advances
in neurovascular disease, these options must be carefully
assessed and compared to existing modalities to ascertain
the best practices for our patients. Within this compilation
of studies, we hope to elucidate areas of uncertainty, recent
developments, and clinical necessity.
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